Trial Profile
A Study to Evaluate the Efficacy and Safety of 15mg BID Losmapimod (GW856553) Compared to Placebo in Frequently Exacerbating Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Losmapimod (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 01 Aug 2016 Status changed from recruiting to completed.
- 28 May 2016 The trial was completed in Germany.
- 13 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.